Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
MULTICENTER STUDY
Reuben Ben-David, Francesco Pellegrino, Parissa Alerasool, Neeraja Tillu, Etienne Lavallee, Kyrollis Attalla, Nikhil Waingankar, Sfakianos P John, Reza Mehrazin, Marco Moschini, Alberto Martini, Sebastian Edeling, Alberto Briganti, Francesco Montorsi, Peter Wiklund
BACKGROUND: Robotic-assisted radical cystectomy (RARC) offers decreased blood loss during surgery, shorter hospital length of stay, and lower risk for thromboembolic events without hindering oncological outcomes. Cutaneous ureterostomies (UCS) are a seldom utilized diversion that can be a suitable alternative for a selected group of patients with competing co-morbidities and limited life expectancy. OBJECTIVE: To describe operative and perioperative characteristics as well as oncological outcomes for patients that underwent RARC + UCS...
April 23, 2024: World Journal of Urology
#2
JOURNAL ARTICLE
G Sorce, A Stabile, F Pellegrino, E Mazzone, A Mattei, L Afferi, S Serni, A Minervini, M Roumiguiè, B Malavaud, M Valerio, A Rakauskas, G Marra, P Gontero, F Porpiglia, H Guo, J Zhuang, G Gandaglia, F Montorsi, A Briganti
PURPOSE: Although targeted biopsies (TBx) are associated with improved disease assessment, concerns have been raised regarding the risk of prostate cancer (PCa) overgrading due to more accurate biopsy core deployment in the index lesion. METHODS: We identified 1672 patients treated with radical prostatectomy (RP) with a positive mpMRI and ISUP ≥ 2 PCa detected via systematic biopsy (SBx) plus TBx. We compared downgrading rates at RP (ISUP 4-5, 3, and 2 at biopsy, to a lower ISUP) for PCa detected via SBx only (group 1), via TBx only (group 2), and eventually for PCa detected with the same ISUP 2-5 at both SBx and TBx (group 3), using multivariable logistic regression models (MVA)...
April 22, 2024: World Journal of Urology
#3
REVIEW
Giuseppe Basile, Andrea Gallioli, Pietro Diana, Anthony Gallagher, Alessandro Larcher, Markus Graefen, Nina Harke, Olivier Traxer, Derya Tilki, Henk Van Der Poel, Esteban Emiliani, Oriol Angerri, Christian Wagner, Francesco Montorsi, Peter Wiklund, Bhaskar Somani, Nicolò Buffi, Alex Mottrie, Evangelos Liatsikos, Alberto Breda
BACKGROUND AND OBJECTIVE: Different training programs have been developed to improve trainee outcomes in urology. However, evidence on the optimal training methodology is sparse. Our aim was to provide a comprehensive description of the training programs available for urological robotic surgery and endourology, assess their validity, and highlight the fundamental elements of future training pathways. METHODS: We systematically reviewed the literature using PubMed/Medline, Embase, and Web of Science databases...
April 20, 2024: European Urology
#4
JOURNAL ARTICLE
Francesco Cei, Alessandro Larcher, Giuseppe Rosiello, Giuseppe Basile, Giacomo Musso, Chiara Re, Giuseppe Fallara, Federico Belladelli, Giorgio Brembilla, Giorgia Guazzarotti, Francesco De Cobelli, Laura Marandino, Andrea Necchi, Alberto Briganti, Andrea Salonia, Roberto Bertini, Francesco Montorsi, Umberto Capitanio
PURPOSE: In absence of predictive models, preoperative estimation of the probability of completing partial (PN) relative to radical nephrectomy (RN) is invariably inaccurate and subjective. We aimed to develop an evidence-based model to assess objectively the probability of PN completion based on patients' characteristics, tumor's complexity, urologist expertise and surgical approach. DESIGN, SETTING AND PARTICIPANTS: 675 patients treated with PN or RN for cT1-2 cN0 cM0 renal mass by seven surgeons at one single experienced centre from 2000 to 2019...
April 21, 2024: Urologic Oncology
#5
JOURNAL ARTICLE
Mattia Longoni, Pietro Scilipoti, Chiara Re, Giuseppe Rosiello, Luigi Nocera, Francesco Pellegrino, Giuseppe Basile, Mario de Angelis, Leonardo Quarta, Giusy Burgio, Andrea Necchi, Antonio Cigliola, Arturo Chiti, Maria Picchio, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Marco Moschini
OBJECTIVE: To assess the diagnostic performance of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder cancer (BCa). MATERIALS AND METHODS: This analysis was based on a cohort of 199 BCa patients undergoing RC and bilateral PLND between 2015 and 2022. Neoadjuvant chemotherapy (NAC) or immunotherapy (NAI) was administered after oncological evaluation...
April 15, 2024: BJU International
#6
JOURNAL ARTICLE
Donato Cannoletta, Greta Pettenuzzo, Antony Pellegrino, Luca A Morgantini, Ruben Sauer, Juan R Torres-Anguiano, Elio Mazzone, Alessandro Antonelli, Francesco Montorsi, Alberto Briganti, Simone Crivellaro
PURPOSE: This study aimed to assess early outcomes of the single-port (SP) robotic Low Anterior Access (LAA) for all upper urinary tract surgeries. Additionally, it aimed to explore the impact of clinical factors, notably Body Mass Index (BMI), on post-operative outcomes and length of hospital stay. MATERIALS AND METHODS: Overall, 76 consecutive patients underwent SP robotic surgery with LAA involving all upper urinary tract pathologies, with data collected prospectively...
April 13, 2024: Journal of Endourology
#7
JOURNAL ARTICLE
Mario de Angelis, Andrea Baudo, Carolin Siech, Letizia Maria Ippolita Jannello, Francesco Di Bello, Jordan A Goyal, Zhe Tian, Nicola Longo, Ottavio de Cobelli, Felix K H Chun, Fred Saad, Shahrokh F Shariat, Luca Carmignani, Giorgio Gandaglia, Marco Moschini, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz
BACKGROUND: Trimodal therapy is considered the most validated bladder-sparing treatment in patients with organ-confined urothelial carcinoma of the urinary bladder (T2N0M0). However, scarce evidence exists regarding cancer-specific mortality (CSM) differences between trimodal therapy and other non-extirpative multimodal treatment options such as radiotherapy alone after transurethral resection (TURBT + RT) or chemotherapy alone after transurethral resection (TURBT + CT). METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified T2N0M0 patients treated with either trimodal therapy, TURBT + CT, or TURBT + RT...
March 27, 2024: Cancers
#8
JOURNAL ARTICLE
Simone Cilio, Paolo Capogrosso, Edoardo Pozzi, Federico Belladelli, Christian Corsini, Massimiliano Raffo, Luigi Candela, Giuseppe Fallara, Luca Boeri, Alessia d'Arma, Ciro Imbimbo, Vincenzo Mirone, Francesco Montorsi, Andrea Salonia
BACKGROUND: Phosphodiesterase 5 inhibitors (PDE5is) represent a first-line pharmacological therapy for erectile dysfunction (ED). Men could obtain PDE5is for recreational purposes without any proper medical prescription. OBJECTIVE: We aimed to analyze clinical characteristics of patients who already used any PDE5i for ED without previous formal medical prescription. MATERIALS AND METHODS: Data from 2012 heterosexual, sexually active men seeking first medical help for ED at our outpatient clinic between 2005 and 2022 were analyzed...
April 8, 2024: Andrology
#9
JOURNAL ARTICLE
Daniele Robesti, Andrea Gallina, Francesco Montorsi, Alberto Briganti, Nicola Fossati
PURPOSE OF REVIEW: The implementation of PET with prostate-specific membrane antigen (PSMA) tracer as primary staging tool occurred recently. Since its introduction, a novel category of patients emerged, with negative staging at conventional imaging, and positive molecular imaging. Local treatment in these patients might be associated with improved oncological outcomes when combined with systemic therapy. However, its impact on oligometastatic prostate cancer (omPCa) remains unknown. In this review, we aimed at investigating the role of cytoreductive radical prostatectomy (cRP) in oligometastatic disease at molecular imaging...
April 8, 2024: Current Opinion in Urology
#10
JOURNAL ARTICLE
Giuseppe Chiarelli, Alex Stephens, Marco Finati, Giuseppe Ottone Cirulli, Edoardo Beatrici, Dejan K Filipas, Sohrab Arora, Shane Tinsley, Mahendra Bhandari, Giuseppe Carrieri, Quoc-Dien Trinh, Alberto Briganti, Francesco Montorsi, Giovanni Lughezzani, Nicolò Buffi, Craig Rogers, Firas Abdollah
PURPOSE: We aimed to assess the appropriateness of ChatGPT in providing answers related to prostate cancer (PCa) screening, comparing GPT-3.5 and GPT-4. METHODS: A committee of five reviewers designed 30 questions related to PCa screening, categorized into three difficulty levels. The questions were formulated identically for both GPTs three times, varying the prompts. Each reviewer assigned a score for accuracy, clarity, and conciseness. The readability was assessed by the Flesch Kincaid Grade (FKG) and Flesch Reading Ease (FRE)...
April 2, 2024: International Urology and Nephrology
#11
JOURNAL ARTICLE
Aitor Blanco-Míguez, Sara Carloni, Cindy Cardenas, Carola Conca Dioguardi, Luca Lambroia, Giovanni Capretti, Gennaro Nappo, Alessandro Fugazza, Antonio Capogreco, Federica Armanini, Francesco Asnicar, Leonard Dubois, Davide Golzato, Paolo Manghi, Federica Pinto, Cristina Scuderi, Erminia Casari, Marco Montorsi, Andrea Anderloni, Maria Rescigno, Alessandro Repici, Alessandro Zerbi, Clelia Peano, Sabrina Tamburini, Roberto Rusconi, Nicola Segata
Malignant bile duct obstruction is typically treated by biliary stenting, which however increases the risk of bacterial infections. Here, we analyzed the microbial content of the biliary stents from 56 patients finding widespread microbial colonization. Seventeen of 36 prevalent stent species are common oral microbiome members, associate with disease conditions when present in the gut, and include dozens of biofilm- and antimicrobial resistance-related genes. This work provides an overview of the microbial communities populating the stents...
March 30, 2024: NPJ Biofilms and Microbiomes
#12
JOURNAL ARTICLE
Valentina Da Prat, Lucia Aretano, Marco Moschini, Arianna Bettiga, Silvia Crotti, Francesca De Simeis, Emanuele Cereda, Amanda Casirati, Andrea Pontara, Federica Invernizzi, Catherine Klersy, Giulia Gambini, Valeria Musella, Carlo Marchetti, Alberto Briganti, Paolo Cotogni, Richard Naspro, Francesco Montorsi, Riccardo Caccialanza
Radical cystectomy (RC) with pelvic lymph node dissection is the standard treatment for patients with limited-stage muscle-invasive bladder cancer. RC is associated with a complication rate of approximately 50-88%. Immunonutrition (IMN) refers to the administration of substrates, such as omega-3 fatty acids, arginine, glutamine, and nucleotides, that modulate the immune response. IMN has been associated with improved outcomes following surgery for esophagogastric, colorectal and pancreatic cancer. In this paper, we describe a study protocol for a multicentre, randomised, open-label clinical trial to evaluate the effect of IMN in patients undergoing RC for bladder cancer...
March 20, 2024: Healthcare (Basel, Switzerland)
#13
JOURNAL ARTICLE
Mario de Angelis, Simone Morra, Lukas Scheipner, Carolin Siech, Letizia Maria Ippolita Jannello, Andrea Baudo, Jordan A Goyal, Zhe Tian, Nicola Longo, Sascha Ahyai, Ottavio de Cobelli, Felix K H Chun, Fred Saad, Shahrokh F Shariat, Luca Carmignani, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz
PURPOSE: Radiotherapy (RT) represents a treatment option for small renal masses with proven feasibility and tolerability. However, it has never been directly compared to partial nephrectomy (PN) with cancer-specific mortality (CSM) as an endpoint. METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified T1aN0M0 renal cell carcinoma (RCC) patients treated with RT or PN. We relied on 1:1 propensity score matching (PSM) for age, tumor size and histology...
March 26, 2024: World Journal of Urology
#14
JOURNAL ARTICLE
Mattia Giuliani, Giulia Santagostino Baldi, Nicolò Capra, Alice Bonomi, Chiara Marzorati, Valeria Sebri, Paolo Guiddi, Piero Montorsi, Gabriella Pravettoni, Daniela Trabattoni
INTRODUCTION: Cardiovascular diseases are the leading cause of death among women. Prevention programmes underscore the need to address women-specific risk factors. Additionally, mental well-being is a significant aspect to consider when grappling with cardiovascular disease in women, particularly depression, anxiety, distress, and personality traits. This study aimed to create "at-risk" psychological profiles for women without prior cardiovascular disease history and to evaluate the association between anxiety, depression, distress, and Type-D personality traits with increased cardiovascular risk over 10 years...
2024: Frontiers in Cardiovascular Medicine
#15
JOURNAL ARTICLE
Francesco Pellegrino, Alberto Martini, Ugo Giovanni Falagario, Juhana Rautiola, Antonio Russo, Laura S Mertens, Luca Di Gianfrancesco, Carlo Andrea Bravi, Jonathan Vollemaere, Muhammad Abdeen, Marco Moschini, Mikolaj Mendrek, Eirik Kjøbli, Stephan Buse, Carl Wijburg, Alae Touzani, Guillaume Ploussard, Alessandro Antonelli, Laura Schwenk, Jan Ebbing, Nikhil Vasdev, Gabriel Froelicher, Hubert John, Abdullah Erdem Canda, Mevlana Derya Balbay, Marcel Stoll, Sebastian Edeling, Camille Berquin, Charles Van Praet, Sami-Ramzi Leyh-Bannurah, Stefan Siemer, Michael Stoeckle, Alexander Mottrie, Frederiek D'Hondt, Alessandro Crestani, Angelo Porreca, Alberto Briganti, Francesco Montorsi, Hendrik van der Poel, Karel Dacaestecker, Richard Gaston, Abolfazl Hosseini, N Peter Wiklund
No abstract text is available yet for this article.
March 21, 2024: BJU International
#16
JOURNAL ARTICLE
Margherita Montorsi, Carlotta Pucci, Daniele De Pasquale, Attilio Marino, Maria Cristina Ceccarelli, Martina Mazzuferi, Martina Bartolucci, Andrea Petretto, Mirko Prato, Doriana Debellis, Giorgio De Simoni, Giammarino Pugliese, Massimiliano Labardi, Gianni Ciofani
Glioblastoma multiforme (GBM) is the most aggressive brain cancer, characterized by a rapid and drug-resistant progression. GBM "builds" around its primary core a genetically heterogeneous tumor-microenvironment (TME), recruiting surrounding healthy brain cells by releasing various intercellular signals. Glioma-associated microglia (GAM) represent the largest population of collaborating cells, which, in the TME, usually exhibit the anti-inflammatory M2 phenotype, thus promoting an immunosuppressing environment that helps tumor growth...
March 20, 2024: Advanced Healthcare Materials
#17
JOURNAL ARTICLE
Mario de Angelis, Andrea Baudo, Carolin Siech, Letizia Maria Ippolita Jannello, Francesco Di Bello, Jordan A Goyal, Zhe Tian, Nicola Longo, Ottavio de Cobelli, Felix K H Chun, Fred Saad, Shahrokh F Shariat, Luca Carmignani, Giorgio Gandaglia, Marco Moschini, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz
INTRODUCTION: Trimodal therapy (TMT) is the most validated bladder-sparing treatment for organ-confined urothelial carcinoma of the urinary bladder (OC UCUB, namely cT2N0M0). However, it is unknown if barriers to the use of TMT or cancer-specific mortality (CSM) differences exist according to race/ethnicity. We addressed this knowledge gap. MATERIAL AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified OC UCUB patients aged from 18 to 85 treated with radical cystectomy (RC) or TMT...
March 20, 2024: Journal of Racial and Ethnic Health Disparities
#18
JOURNAL ARTICLE
Mario de Angelis, Andrea Baudo, Carolin Siech, Letizia Maria Ippolita Jannello, Francesco Di Bello, Jordan A Goyal, Zhe Tian, Nicola Longo, Ottavio de Cobelli, Felix K H Chun, Fred Saad, Shahrokh F Shariat, Luca Carmignani, Giorgio Gandaglia, Marco Moschini, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz
OBJECTIVE: To address cancer-specific mortality free-survival (CSM-FS) differences in patients with urothelial carcinoma of the urinary bladder (UCUB) vs non-UCUB who underwent trimodal therapy (TMT), according to organ confined (OC: T2N0M0) vs non-organ confined (NOC: T3-4NanyM0 or TanyN1-3M0) clinical stages. PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients with cT2-T4N0-N3M0 bladder cancer treated with TMT, defined as the combination of transurethral resection of bladder tumour, chemotherapy, and radiotherapy...
March 18, 2024: BJU International
#19
JOURNAL ARTICLE
Francesco Pellegrino, Pietro Scilipoti, Giuseppe Rosiello, Mattia Longoni, Riccardo Leni, Giuseppe Basile, Leonardo Quarta, Paolo Zaurito, Chiara Re, Mario de Angelis, Francesco Cattafi, Giusy Burgio, Giorgio Gandaglia, Francesco Montorsi, Alberto Briganti, Marco Moschini
No abstract text is available yet for this article.
March 14, 2024: BJU International
#20
JOURNAL ARTICLE
Francesco Barletta, Stefano Tappero, Simone Morra, Reha-Baris Incesu, Cristina Cano Garcia, Mattia L Piccinelli, Lukas Scheipner, Zhe Tian, Giorgio Gandaglia, Armando Stabile, Elio Mazzone, Carlo Terrone, Nicola Longo, Derya Tilki, Felix K H Chun, Ottavio de Cobelli, Sascha Ahyai, Fred Saad, Shahrokh F Shariat, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz
OBJECTIVES: To identify low cancer-specific mortality (CSM) risk lymph node-positive (pN1) radical prostatectomy (RP) patients. METHODS: Within Surveillance, Epidemiology and End Results database (2010-2015) pN1 RP patients were identified. Kaplan-Meier plots and multivariable Cox-regression (MCR) models were used. Pathological characteristics were used to identify patients at lowest CSM risk. RESULTS: Overall, 2197 pN1 RP patients were identified...
March 12, 2024: Journal of Surgical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
